Table 2.
Adverse events determined by the clinical investigator to be at least possibly related to the BsIgG products.
| AE Description | Group |
|||
|---|---|---|---|---|
| Placebo (n = 20) |
Anti-CS6 (n = 19) |
Anti-B7A (n = 20) |
Total (n = 59) |
|
| Abdominal cramps, n(%) | 1 (5.0) | 2 (10.5) | 0 (0.0) | 3 (5.1) |
| Anorexia, n(%) | 0 (0.0) | 0 (0.0) | 1 (5.0) | 1 (1.7) |
| Bloating, n(%) | 0 (0.0) | 1 (5.3) | 2 (10.0) | 3 (5.1) |
| Flatulence, n(%) | 2 (10.0) | 3 (15.8) | 4 (20.0) | 9 (15.3) |
| Headache, n(%) | 0 (0.0) | 0 (0.0) | 2 (10.0) | 2 (3.4) |
| Nausea, n(%) | 0 (0.0) | 0 (0.0) | 1 (5.0) | 1 (1.7) |
| Urgency, n(%) | 1 (5.0) | 0 (0.0) | 0 (0.0) | 1 (1.7) |
All reported symptoms were mild except for 1 moderate episode of abdominal cramps.